DarioHealth (NASDAQ: DRIO), a leader in the global digital health market, announced the presentation of research at ISPOR 2023, the leading global conference for health economics and outcomes research. The conference was on May 7–10, 2023, in Boston. The research presented came from a retrospective cohort study that analyzed real-world data of users and nonusers of a digital health solution; it was the first study completed by Sanofi U.S. under its strategic agreement with Dario. According to the announcement, the research shows a 9.3% reduction in all cause healthcare resource utilization rates, including 23.5% decrease in hospitalization for Dario users. The study is a strong indication that a whole-health approach to managing chronic conditions such as diabetes can potentially reduce utilization rates that lead to potential cost savings. The study was the first of its kind in digital health research. “We are incredibly proud of this new research demonstrating Dario’s ability to potentially reduce health care utilization through a holistic, user-centric digital health solution,” said DarioHealth chief medical officer Omar Manejwala in the press release. “These results are important not only to our clients and partners who are looking for solutions to help reduce the cost of care but also to the market as we push for more accountability in digital health research. . . . We are indebted to our strategic partners at Sanofi venturing together on the journey to accelerate innovation in digital health, and this study marks another major accomplishment for our partnership.”

To view the full press release, visit https://ibn.fm/jJweX

About DarioHealth Corp.

DarioHealth Corp. is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric, multichronic condition digital therapeutics platform. Dario’s platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health. The company’s user-centric platform offers people continuous and customized care for health, disrupting the traditional episodic approach to healthcare. This approach empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention and results, and making the right thing to do the easy thing to do. Dario provides its highly user-rated solutions globally to health plans and other payors, self-insured employers and providers of care as well as directly to consumers. For more information about the company, please visit www.DarioHealth.com.

NOTE TO INVESTORS: The latest news and updates relating to DRIO are available in the company’s newsroom at http://ibn.fm/DRIO

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com

InvestorWire is part of the InvestorBrandNetwork